HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Clinicopathologic Conference, Acute human immunodeficiency virus type 1
NEJM 385:641-648, Case 24-2021, 2021
Clinicopathologic Conference, Cystoisospora Belli Enteritis and HIV Infection
NEJM 365:2306-2316, Case 38-2011, 2011
Clinicopath Conf, Acute HIV-1 Infection
NEJM 360:1540-1548, Case 11-2009, 2009
HIV-associated Neurologic Disease Incidence Changes: Multicenter AIDS Cohort Study, 1990-1998
Neurol 56:257-260, Sacktor,N.,et al, 2001
Incidence and Prevalence of Neurological Disorders Associated with HIV Since the Introduction of Highly Active Antiretroviral Therapy (HAART)
JNNP 69:376-380, Maschke,M. et al, 2000
AIDS-Related Focal Brain Lesions in the Era of Highly Active Antiretroviral Therapy
Neurol 55:1194-1200, Ammassari,A.,et al, 2000
HAART Improves Prognosis in HIV-Associated Progressive Multifocal Leukoencephalopathy
Neurol 52:623-625,440, Clifford,D.B.,et al, 1999
Regress of HIV Enceph & Basal Ganglia Signal Intensity Abnor MRI in AIDS after Protease Inhibitor
Neuroradiology 206:491-498, Filippi,C.G.,et al, 1998
Progressive Multifocal Leukoencephalopathy, HIV, and Highly Active Antiretroviral Therapy
NEJM 339:848-849, Cinque,P.,et al, 1998
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997